STAT3 and non-small cell lung carcinoma: JAK/STAT3 pathway, suggested as a promising therapeutic strategy (Thomas et al., 2015), was inhibited by physalin A, both by suppressing JAK receptor phosphorylation and preventing STAT3 translocation to the nucleus and, consequently, inhibiting its transcriptional activity in non-small lung cell carcinoma (Zhu et al., 2016).